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Abstract: A high-performance liquid chromatographic (HPLC) method has been developed for the separation and deter-
mination of S- and R-enantiomers of betaxolol in tablets and ophthalmic preparations. Baseline resolution was achieved by 
using teicoplanin macrocyclic antibiotic chiral stationary phase (CSP) known as Chirobiotic T with ﬂ  uorescence detection 
at excitation/emission wavelengths 275/305 nm. The polar ionic mobile phase (PIM) consists of methanol-glacial acetic 
acid-triethylamine, (100:0.020:0.025, v/v/v) has been used at a ﬂ  ow rate of 1.5 ml/min. All analytes with S-(–)-atenolol as 
internal standard were conducted at ambient temperature. The method is highly speciﬁ  c where another coformulated com-
pounds did not interfere. The stability of betaxolol enantiomers under different degree of temperature also studied. The 
results showed that it is stable for at least 7 days at 70
oC. The method validated for its linearity, accuracy, precision and 
robustness. Experimental design was used during validation to evaluate method robustness. Using the chromatographic 
conditions described, S- and R-betaxolol were well resolved with mean retention times of 11.3 and 12.6 min, respectively. 
Linear response (r > 0.997) was observed over the range of 10–500 ng/ml of betaxolol enantiomers, with detection limit of 
5 ng/ml. The recoveries of S- and R-betaxolol from tablets and ophthalmic preparation ranged from 97.4 to 101.4% and 
98.0 to 102.0%, respectively. The mean relative standard deviation (R.S.D.%) for both enantiomers were 1.1–1.4% and 
1.3–1.7% in tablets and ophthalmic solution, respectively.
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Introduction
The determination of enantiomeric purity of pharmaceuticals is subject to severe attention from the 
clinical and toxicological point of view. Prior to the approval of a new racemic drug, the enantiomers must 
be analytically and unequivocally separated, and the pharmacological effects as well as the metabolic 
pathways must be studied separately for each enantiomer [1]. This implies an ever increasing demand for 
pure enantiomeric compounds and for pertinent enantioselective technologies. Enantiomeric resolutions 
have acquired an important position in all stages of drug development process. Therefore, the development 
of new methods for efﬁ  cient chiral separations and quantitation is more than necessary [2].
In last two decades, high performance liquid chromatography (HPLC) has become one of the mostly 
applied techniques in the chiral separation of different racemates [3,4]. Several chiral stationary phases 
(CSPs) have been developed and used for the chiral separation of a variety of racemates. Among these 
CSPs, macrocyclic glycopeptide antibiotic-based CSP are very important as they have achieved a great 
reputation in the ﬁ  eld of chiral separation. The importance of this type of CSP includes its ease of use, 
reproducible results and a wide range of applications [5–7].
Macrocyclic antibiotics have been introduced by Armstrong et al. as powerful chiral selector [8–10]. 
The glycopeptides macrocyclic antibiotics such as teicoplanin and vancomycin have been widely used 
as a CSP and a great variety of racemic compounds have been resolved on them [11,12]. The enanti-
oselectivity of these chiral selectors due to several reasons: (a) they are amphoteric (i.e. contain acidic 
and basic ionizable groups); (b) they have the necessary geometry and functionalities that accentuate 
chiral recognition in solution; and (c) they contain both hydrophilic and hydrophobic moieties [13].
The possible bonding between the enantiomers and the macrocyclic glycopeptide antibiotic CSP has 
been reviewed [14]. The most important bonding involved is π-π complexation, hydrogen bonding, 
inclusion complexation, dipole interactions, steric interactions and ionic and cationic bindings. These 
bonding are a result of the complex structures of this CSP, which consists of sugar moieties, phenyl, 
quinoline and thiazole rings, along with several chiral centers, inclusion baskets, hydrogen donor and 
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acceptor sites. It has been reported that these 
bonding sites are responsible for the surprising 
chiral selectivities of these antibiotics [6,8].
Betaxolol hydrochloride, 1-[4-[2-(cyclopropyl
methoxy)ethyl]-phenoxy]-3-[(1-
methylethyl)amino]-2-propanol, is a cardioselec-
tive β-adrenergic antagonist. It exhibits high and 
consistent bioavailability (70–90%) and a long 
terminal half-life of (13–20 h) [15]. The drug, 
marketed as a racemic mixture, is highly efﬁ  ca-
cious for the treatment of hypertension and 
glaucoma [16].
The resolution of betaxolol enantiomers was 
ﬁ  rst reported using a lengthy derivatization with 
R(–)-naphthylethylisocyanate by reversed-phase 
HPLC and ﬂ  uorimetric detection[17]. A direct 
method for the enantiomeric separation of betax-
olol on Chiralcel OD column has been developed 
using UV detection [16]. The separation of betax-
olol on a cellulose tris(4-methylbenzoate) chiral 
stationary phase without derivatization via normal-
phase HPLC was also reported [18].
This method is ﬁ  rst direct reversed-phase chiral 
HPLC assay in pharmaceutical products utilizing 
teicoplanin CSP and fluorimetric detection. The 
method is highly selective where other co-formulated 
substances did not interfere in the determination.
Experimental
Chromatographic conditions
The HPLC instrument (Jasco, Japan) equipped with 
a pump (model PU-980), a ﬂ  uorescence detector 
(model FP-920), a 20 µl injector and the instrument 
is connected to LG computer. The CSP used in this 
study was the macrolide-type antibiotic teico-
planin, known as Chirobiotic T (150 × 4.6 mm i.d.) 
purchased from Advanced Separation Technolo-
gies (Whippany, NJ, U.S.A.). The mobile phase 
was methanol-glacial acetic acid-triethylamine 
(100:0.020:0.025, v/v/v). The mobile phase was 
ﬁ  ltered through a Millipore membrane ﬁ  lter (0.2 µm) 
from Nihon, Millipore (Yonezawa, Japan) and 
degassed before used. The ﬂ  ow rate was 1.5 ml/min 
and the detection wavelengths (FL) were set at 275 
nm for excitation and 305 nm for emission.
Chemicals
Betaxolol hydrochloride, S-betaxolol and R-
betaxolol were obtained from RBI (Natick, MA, 
U.S.A.). S-(–)-Atenolol was obtained from Sigma 
Chemical Co. (St Louis, MO, U.S.A.). HPLC-
grade methanol, analytical grade triethylamine and 
glacial acetic acid were purchased from BDH 
Chemicals (Poole, U.K). Kerlone
® 20 mg tablet 
(containing 20 mg of betaxolol hydrochloride/
tablet) was obtained from Laboratoires Synthelabo 
( Le Plessis-Robinson/France) and Betoptic
® 0.5% 
drop (containing 0.5% betaxolol hydrochloride and 
0.01% benzalkonium chloride) was obtained from 
Laboratoires Alcon (Rueil-Malmaison Cedex, 
France).
Preparation of standard
stock solutions
Stock solution containing 1 mg/ml of S- and R-
betaxolol were prepared in methanol and serial 
dilutions with the same solvent were made to cover 
the working range. The internal standard S-(–)-
atenolol was prepared in methanol to give a 
concentration of 1mg/ml. The solutions were kept 
in a refrigerator.
Preparation of standard solutions
of tablets
Ten tablets were ground and powdered, an accu-
rately weighed portion equivalent to 20 mg 
betaxolol was transferred to 100 ml volumetric 
ﬂ  ask diluted to the mark with methanol. The solu-
tion was sonicated for 15 min, centrifuged at 3000 
rpm for 10 min. Accurately measured aliquots of 
the supernatant were transferred to 5 ml volumetric 
ﬂ  asks containing 70 µl of the internal standard and 
diluted to 5 ml with methanol to give ﬁ  nal concen-
tration of 50, 250 and 400 ng/ml of betaxolol.
Preparation of standard solution
of ophthalmic drops
The content of ten ophthalmic solutions (0.5%) 
were mixed well and 1 ml was transferred into 
100 ml volumetric ﬂ  ask and diluted to the mark 
with methanol. Appropriate dilution with the same 
solvent was made to provide a solution containing 
500 ng/ml of betaxolol. Accurately measured 
aliquots of this solution were transferred to 5 ml 
volumetric ﬂ  ask containing 70 µl of the internal 
standard and diluted to 5 ml with methanol to give 
ﬁ  nal concentration of 50, 250 and 400 ng/ml of 
betaxolol.
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Linearity
Aliquot volumes of the ﬁ  nal solution of S(–)- and 
R(+)-betaxolol were transferred to a series of 5 ml 
volumetric ﬂ  asks to produce solutions covering the 
concentration range from 10–500 ng/ml. A volume 
equivalent to 70 µl of S-(–)-atenolol was added to 
each ﬂ  ask and the solution was diluted to 5 ml with 
methanol. A 20 µl of each standard solution was 
injected into the chromatographic system and the 
chromatograms were recorded. Calibration stan-
dards of each concentration were analyzed in 
triplicate. Calibration curves of betaxolol enantio-
mers were constructed using normalized drug/
internal standard peak area ratio versus nominal 
concentrations of the analyte. Least squares linear 
regression analysis of the data gave slope, inter-
cept, and correlation coefﬁ  cient data. The corre-
sponding regression equations were derived for the 
analyte.
Quantitation
A 20 µl of the selected assay solutions of tablets 
and ophthalmic drops were injected into the chro-
matographic system and the chromatograms were 
recorded. The nominal contents of the drug in each 
formulation were calculated from the linear regres-
sion equations. The recovery and the RSD were 
calculated.
Speciﬁ  city
The speciﬁ  city of the method was investigated by 
observing any interference encountered from 
coformulated benzalkonium chloride in ophthalmic 
solution and other excipients present in the 
tablets.
Stability of ophthalmic solutions
The stability of ophthalmic solutions was tested 
by the developed HPLC method over a period of 
7 days. The freshly prepared and the 7 day-stored 
samples at room temperature, 30, 50 and 70
oC were 
analyzed by the proposed HPLC method. The 
concentrations of the stored samples were calcu-
lated and compared to that of the freshly prepared 
samples.
Validation
The limit of detection (LOD) and the limit of 
quantiﬁ  cation (LOQ) were determined as 3 and 10 
times the baseline noise, respectively [19]. The 
results of the statistical analysis of the experimental 
data, such as the slopes, the intercepts, the correla-
tion coefﬁ  cients obtained by the linear squares 
treatment of the results along with standard devia-
tion of the slope (Sb) and intercept (Sa) on the 
ordinate and the standard deviation of the residuals 
(Sy/x) was shown. The good linearity of the calibra-
tion graphs and the negligible scatter of experi-
mental points are clearly evident by the values of 
the correlation coefﬁ  cient and standard deviation. 
The robustness of the method is demonstrated by 
the versatility of the experimental factors that affect 
the peak area.
Results and discussion
The HPLC method carried out in this study, aimed 
at developing a chromatographic system, capable 
of eluting and resolving betaxolol enantiomers 
from pharmaceutical preparations (Fig. 1). The use 
of methanol-based mobile phases containing 
different triethylamine and acetic acid ratios was 
investigated for the separation of enantiomers of 
betaxolol on teicoplanin column. The best results 
in terms of resolution, analysis time and separation 
factor were obtained with mobile phase consisted 
of methanol-glacial acetic acid-triethylamine 
(100:0.020:0.025, v/v/v) (Table1). No enantiosep-
aration were observed in the absence of triethyl-
amine. This could be explained on the basis of 
strong repulsive effects between the protonated 
amino groups of the analyte molecules and of the 
CSP. An increase of the triethylamine concentra-
tion in the mobile phase (to about 0.1%) decreased 
the retention factors of the studied analytes. 
Increasing the concentration of acetic acid in the 
mobile phase (to about 0.1%) also decreased the 
retention factors of the studied analytes. This 
demonstrates that it is the concentration of acetic 
acid and triethylamine in mobile phase that has a 
substantial inﬂ  uence on the retention factors and 
not the ionic strength of the mobile phase that was 
constant.
Macrocyclic antibiotic chiral stationary phases 
have been widely used for enantiomers resolution 
because they are very effectively for the enan-
tioseparation of anionic compounds. The selec-
tivity towards these compounds is because of the 
presence of amine groups in the chiral selector 
[20]. If the compound has more than one functional 
group capable of interacting with the stationary 
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phase and at least one of those groups is on or near 
the stereogenic center, then the ﬁ  rst mobile phase 
choice would be the polar ionic mobile phase 
(PIM). Due to the strong polar groups present in 
the macrocyclic peptides, it was possible to convert 
the original mobile phase concept to 100% meth-
anol with an acid/base added to effect selectivity 
[20]. The key factor in obtaining complete resolu-
tion is still the ratio of acid to base [5]. The impor-
tance and superiority of macrocyclic antibiotics as 
chiral selector, in comparison with other chiral 
selector, is because they can be used in normal and 
reversed phases with greater stability and capacity 
[21]. The polar ionic mobile phase (PIM) has been 
described as a developed method to obtain difﬁ  cult 
enantioselective separation with macrocyclic 
antibiotic-based CSP [22]. This approach uses a 
non-aqueous polar component (methanol) with 
both glacial acetic acid and triethylamine, which 
are necessary to achieve enantioseparation.
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Fig. 1. The chemical structure of (A) S-betaxolol, (B) R-betaxolol and (C) S-(–)-atenolol (IS).
Table 1. Chromatographic parameters for betaxolol enantiomers and the internal standard S-(–)-atenolol.
Analyte  Rs
a  α
b  K
c,d  TR (min)
d
S-betaxolol  1.83  1.12  6.62 ± 0.02  11.36 ± 0.03
R-betaxolol  6.98  1.69  7.46 ± 0.04  12.62 ± 0.05
S-(–)-atenolol 
e 
e  12.61 ± 0.01  20.29 ± 0.02
a Rs = (t2 – t1)/0.5(w1+w2)
b Separation factor, calculated as k2/k1
c Capacity factor, calculated as TR – T0 / T0
d Mean ± SD, n = 3
e Not calculated
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The linear regression analysis of betaxolol 
enantiomers in pure solution was constructed by 
plotting the peak area ratio of each enantiomer to 
the internal standard (y) versus analyte concentra-
tion in ng/ml (x). The calibration curves were linear 
in the range of 10–500 ng/ml, with a correlation 
coefficient (r) of 0.996 for both enantiomers 
(Table 2). A typical calibration curve has the 
regression equation of y = 0.005 x – 0.002 for (S)-
betaxolol and y = 0.005 x – 0.003 for (R)-betaxolol. 
The limit of detection (LOD) and the limit of 
quantitation (LOQ) for each enantiomer were 
5 ng/ml and 10 ng/ml, respectively (Table 2). The 
results of the statistical analysis of the experimental 
data, such as the slopes, the intercepts and the 
correlation coefficients obtained by the least 
squares treatment of the results along with standard 
deviation of the slopes and intercepts on the ordi-
nate and the standard deviation of the residuals 
were shown in Table 2. The accuracy of the method 
was tested by analyzing different concentrations 
of standard betaxolol enantiomers. The results were 
expressed as percent recoveries of the particular 
components in the samples (Table 3). The overall 
recoveries of betaxolol enantiomers in standard 
solution by the proposed method were 99.6 and 
99.4% for S- and R-betaxolol, respectively, with 
%RSD of 0.62 for S- and R-betaxolol, respectively, 
indicating that these values were acceptable.
The validity of the method developed here was 
applied to various concentrations taken from the 
pharmaceutical formulations (Kerlone
® 20 mg 
tablet, and Betoptic
® 0.5% drop) for determining 
their content of betaxolol enantiomers. The values 
of the overall drug percentage recoveries and the 
%RSD values of S- and R-betaxolol are presented 
in Table 4, indicating that these values are accept-
able and the method is accurate and precise. 
Benzalkonium chloride, a preservative which is 
coformulated with betaxolol in ophthalmic solu-
tion, did not interfere with the determination of 
betaxolol enantiomers indicating the high speci-
ﬁ  city of the proposed method. Excipients commonly 
coformulated with the studied drug in tablets such 
as magnesium stearate, starch, talk powder and 
binder did not interfere with the determination of 
betaxolol, indicating the high selectivity of the 
method (Fig. 2).
The optimum HPLC conditions set for this 
method have been slightly modiﬁ  ed for samples 
of betaxolol as a mean to evaluate the method 
robustness. The small changes made include the 
ﬂ  ow rate, the detection wavelength, temperature 
and day. Table 5 shows that the percent recoveries 
of betaxolol enantiomers were good under most 
conditions and did not show a signiﬁ  cant change 
when the critical parameters were modified. 
Considering the modiﬁ  cation in the system suit-
ability parameters and the speciﬁ  city of the method, 
as well as carrying the experiment at room temper-
ature, would conclude that the method conditions 
are robust.
The stability of ophthalmic solutions versus 
temperature was tested by the developed HPLC 
over a period of 7 days. The freshly prepared and 
the 7 day-stored samples at room temperature, 30, 
50 and 70
oC were analyzed by the proposed HPLC 
method. The concentrations of betaxolol enantio-
mers in the stored samples were calculated and 
compared to that in freshly prepared samples. 
There is a non signiﬁ  cant difference between the 
stored and freshly prepared samples, indicating the 
possibility of using betaxolol solutions over a 
period of 7 days without degradation.
Table 2. Validation parameters for the determination of betaxolol enantiomers using the proposed method.
Parameter S-betaxolol  R-betaxolol
Concentration range (ng/ml)  10–500  10–500
Intercept (a)  –0.002  –0.003
Slope (b)  0.005  0.005
Correlation coefﬁ  cient (r)  0.996  0.996
Sy/x 0.034  0.036
Sa 0.030  0.031
Sb 0.0004  0.0005
LOD (ng/ml)
a 5  5
LOQ (ng/ml)  10  10
a S/N = 3
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Conclusion
A highly speciﬁ  c high-performance liquid chro-
matographic method has been developed and vali-
dated for the separation and quantification of 
betaxolol enantiomers in tablets and ophthalmic 
solution. The method utilizes a teicoplanin chiral 
stationary phase and ﬂ  uorescence detection. The 
method is selective for the determination of betax-
olol enantiomers in the presence of coformulated 
benzolkonium chloride without interferences. The 
total run time for this method is 25 min, which 
allows processing of over 55 samples per day. This 
method has provided good sensitivity and excellent 
precision and reproducibility.
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Table 4. Determination of betaxolol enantiomers in pharmaceutical preparations by the proposed method.
Pharmaceutical Enantiomer  Nominal  Measured  Recovery
Preparation   conc.(ng/ml)  conc.(ng/ml)  (%)
Kerlone
® 20 mg  S  50  49.50  99.00
tablets
a   250 251.00  100.40
     400 398.40  99.60
Overall recovery        99.66
RSD (%)        0.58
   R 50 49.40  98.80
     250 250.50  100.20
     400 398.80  99.70
Overall recovery        99.56
RSD (%)        0.58
Betoptic
® 0.5%  S  50  50.48  100.96
ophthalmic solution
b   250  248.88  99.55
     400  400.75  100.15
Overall recovery        100.22
RSD (%)        0.58
   R  50  50.43  100.86
     250  248.63  99.45
     400  401.75  100.35
Overall recovery        100.22
RSD (%)        0.58
a Product of Laboratoires Synthelabo (Le Plessis-Robinson / France).
b Product of Laboratoires Alcon ( Rueil-Malmaison Cedex, France).
Table 3. Determination of betaxolol enantiomers in standard solutions by the proposed method.
Analyte Enantiomer  Nominal  Measured Recovery
   conc.(ng/ml)  conc.(ng/ml)  (%)
Betaxolol S  50 49.75  99.50
   250  247.25  98.90
   400  401.60  100.40
Overall recovery        99.60
RSD (%)        0.62
 R  50  49.70  99.40
   250  247.25  98.70
   400  400.80  100.20
Overall recovery        99.43
RSD (%)        0.62
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Table 5. Effect of experimental parameters on percent recoveries of betaxolol enantiomers.
Parameters Modiﬁ  cation  Recovery (%)
  S R
Flow rate (ml/min)  1.2  99.8  99.6
 1.5  98.6  98.8
 1.8  98.4  98.5
Wavelength of excitation (nm)  272  100.8  100.6 
 275  99.6  99.5
 278  100.6  100.5
Wavelength of emission (nm)  302  99.8  100.0
 305  98.9  98.8
 308  100.4  100.6
Temperature
a (
oC) 30  100.1  100.3
 50  98.6  98.7
 70  97.4  97.6
Day
b 1  100.5  102.3
 3  99.4  101.4
 5  100.0  99.7
 7  98.8  98.9
a 7-day stored ophthalmic solutions at 30, 50 and 70
oC. 
b Ophthalmic solutions were stored at room temperature.
Fig. 2 Chromatogram of [I] S-betaxolol,100 ng/ml, [II] R-betaxolol, 100 ng/ml, recovered from Kerlone
® 20 mg tablet and/or Betoptic
® 0.5% 
Drop spiked with [III] 10 µg/ml (S)-(–)-atenolol (IS).
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Research Programs.
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